( May 12, 2026, 8:27 AM EDT) -- ATLANTA — Teva Pharmaceuticals USA Inc. and the two bellwether plaintiffs in the Paragard intrauterine device (IUD) multidistrict litigation responded to an invitation from a federal judge to weigh in on her proposed certified question to the 11th Circuit U.S. Court of Appeals for interlocutory appeal, with both sides arguing that the judge’s question is too narrow in the dispute over what information can retroactively apply as newly acquired information under the U.S. Food and Drug Administration’s changes-being-effected (CBE) regulation....